As of Oct 21
| +0.42 / +8.20%|
The 4 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 10.00, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +80.51% increase from the last price of 5.54.
The current consensus among 6 polled investment analysts is to Hold stock in Merrimack Pharmaceuticals Inc. This rating has held steady since October, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.